Global Circulating Tumor Cells and Cancer Stem Cells Market Growth (Status and Outlook) 2024-2030

Publication ID:

LPI11243147

Publication Date:

November 29, 2024

Pages:

111

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Circulating Tumor Cells and Cancer Stem Cells market size was valued at US$ 14070 million in 2023. With growing demand in downstream market, the Circulating Tumor Cells and Cancer Stem Cells is forecast to a readjusted size of US$ 38710 million by 2030 with a CAGR of 15.6% during review period.
The research report highlights the growth potential of the global Circulating Tumor Cells and Cancer Stem Cells market. Circulating Tumor Cells and Cancer Stem Cells are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Circulating Tumor Cells and Cancer Stem Cells. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Circulating Tumor Cells and Cancer Stem Cells market.
Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs can help to determine the process of metastasis. In contrast with other blood cells, the number of CTCs is very rare in blood which makes them difficult to detect.

Cancer stem cells (CSCs) are cancer cells that have all the classical properties of normal stem cells. Specifically, they are able to both give rise to more copies of themselves and to give rise to all cell types found in the cancer.
The major players in global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market include Janssen, Qiagen, Advanced Cell Diagnostics, etc. North America and Europe are main markets, they occupy about 65% of the global market. CellSearch is the main type, with a share about 70%. Breast Cancer Diagnosis and Treatment, Colorectal Cancer Diagnosis and Treatment are main applications, which hold a share about 60%.
Key Features:
The report on Circulating Tumor Cells and Cancer Stem Cells market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Circulating Tumor Cells and Cancer Stem Cells market. It may include historical data, market segmentation by Type (e.g., Cell Enrichment, Cell Detection), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Circulating Tumor Cells and Cancer Stem Cells market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Circulating Tumor Cells and Cancer Stem Cells market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Circulating Tumor Cells and Cancer Stem Cells industry. This include advancements in Circulating Tumor Cells and Cancer Stem Cells technology, Circulating Tumor Cells and Cancer Stem Cells new entrants, Circulating Tumor Cells and Cancer Stem Cells new investment, and other innovations that are shaping the future of Circulating Tumor Cells and Cancer Stem Cells.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Circulating Tumor Cells and Cancer Stem Cells market. It includes factors influencing customer ' purchasing decisions, preferences for Circulating Tumor Cells and Cancer Stem Cells product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Circulating Tumor Cells and Cancer Stem Cells market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Circulating Tumor Cells and Cancer Stem Cells market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Circulating Tumor Cells and Cancer Stem Cells market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Circulating Tumor Cells and Cancer Stem Cells industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Circulating Tumor Cells and Cancer Stem Cells market.
Market Segmentation:
Circulating Tumor Cells and Cancer Stem Cells market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Cell Enrichment
Cell Detection
CTC Analysis
Segmentation by application
Hospital
NSC
Medical Research Institute
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
QIAGEN Hannover
AVIVA Biosciences
Epic Sciences
ApoCell
Cynvenio Biosystems
Fluxion Biosciences
Rarecells
Janssen Diagnostics
CellTraffix
Silicon Biosystems
Advanced Cell Diagnostics

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Circulating Tumor Cells and Cancer Stem Cells Market Size 2019-2030
2.1.2 Circulating Tumor Cells and Cancer Stem Cells Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Circulating Tumor Cells and Cancer Stem Cells Segment by Type
2.2.1 Cell Enrichment
2.2.2 Cell Detection
2.2.3 CTC Analysis
2.3 Circulating Tumor Cells and Cancer Stem Cells Market Size by Type
2.3.1 Circulating Tumor Cells and Cancer Stem Cells Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Circulating Tumor Cells and Cancer Stem Cells Market Size Market Share by Type (2019-2024)
2.4 Circulating Tumor Cells and Cancer Stem Cells Segment by Application
2.4.1 Hospital
2.4.2 NSC
2.4.3 Medical Research Institute
2.5 Circulating Tumor Cells and Cancer Stem Cells Market Size by Application
2.5.1 Circulating Tumor Cells and Cancer Stem Cells Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Circulating Tumor Cells and Cancer Stem Cells Market Size Market Share by Application (2019-2024)
3 Circulating Tumor Cells and Cancer Stem Cells Market Size by Player
3.1 Circulating Tumor Cells and Cancer Stem Cells Market Size Market Share by Players
3.1.1 Global Circulating Tumor Cells and Cancer Stem Cells Revenue by Players (2019-2024)
3.1.2 Global Circulating Tumor Cells and Cancer Stem Cells Revenue Market Share by Players (2019-2024)
3.2 Global Circulating Tumor Cells and Cancer Stem Cells Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Circulating Tumor Cells and Cancer Stem Cells by Regions
4.1 Circulating Tumor Cells and Cancer Stem Cells Market Size by Regions (2019-2024)
4.2 Americas Circulating Tumor Cells and Cancer Stem Cells Market Size Growth (2019-2024)
4.3 APAC Circulating Tumor Cells and Cancer Stem Cells Market Size Growth (2019-2024)
4.4 Europe Circulating Tumor Cells and Cancer Stem Cells Market Size Growth (2019-2024)
4.5 Middle East & Africa Circulating Tumor Cells and Cancer Stem Cells Market Size Growth (2019-2024)
5 Americas
5.1 Americas Circulating Tumor Cells and Cancer Stem Cells Market Size by Country (2019-2024)
5.2 Americas Circulating Tumor Cells and Cancer Stem Cells Market Size by Type (2019-2024)
5.3 Americas Circulating Tumor Cells and Cancer Stem Cells Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Circulating Tumor Cells and Cancer Stem Cells Market Size by Region (2019-2024)
6.2 APAC Circulating Tumor Cells and Cancer Stem Cells Market Size by Type (2019-2024)
6.3 APAC Circulating Tumor Cells and Cancer Stem Cells Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Circulating Tumor Cells and Cancer Stem Cells by Country (2019-2024)
7.2 Europe Circulating Tumor Cells and Cancer Stem Cells Market Size by Type (2019-2024)
7.3 Europe Circulating Tumor Cells and Cancer Stem Cells Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Circulating Tumor Cells and Cancer Stem Cells by Region (2019-2024)
8.2 Middle East & Africa Circulating Tumor Cells and Cancer Stem Cells Market Size by Type (2019-2024)
8.3 Middle East & Africa Circulating Tumor Cells and Cancer Stem Cells Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Circulating Tumor Cells and Cancer Stem Cells Market Forecast
10.1 Global Circulating Tumor Cells and Cancer Stem Cells Forecast by Regions (2025-2030)
10.1.1 Global Circulating Tumor Cells and Cancer Stem Cells Forecast by Regions (2025-2030)
10.1.2 Americas Circulating Tumor Cells and Cancer Stem Cells Forecast
10.1.3 APAC Circulating Tumor Cells and Cancer Stem Cells Forecast
10.1.4 Europe Circulating Tumor Cells and Cancer Stem Cells Forecast
10.1.5 Middle East & Africa Circulating Tumor Cells and Cancer Stem Cells Forecast
10.2 Americas Circulating Tumor Cells and Cancer Stem Cells Forecast by Country (2025-2030)
10.2.1 United States Circulating Tumor Cells and Cancer Stem Cells Market Forecast
10.2.2 Canada Circulating Tumor Cells and Cancer Stem Cells Market Forecast
10.2.3 Mexico Circulating Tumor Cells and Cancer Stem Cells Market Forecast
10.2.4 Brazil Circulating Tumor Cells and Cancer Stem Cells Market Forecast
10.3 APAC Circulating Tumor Cells and Cancer Stem Cells Forecast by Region (2025-2030)
10.3.1 China Circulating Tumor Cells and Cancer Stem Cells Market Forecast
10.3.2 Japan Circulating Tumor Cells and Cancer Stem Cells Market Forecast
10.3.3 Korea Circulating Tumor Cells and Cancer Stem Cells Market Forecast
10.3.4 Southeast Asia Circulating Tumor Cells and Cancer Stem Cells Market Forecast
10.3.5 India Circulating Tumor Cells and Cancer Stem Cells Market Forecast
10.3.6 Australia Circulating Tumor Cells and Cancer Stem Cells Market Forecast
10.4 Europe Circulating Tumor Cells and Cancer Stem Cells Forecast by Country (2025-2030)
10.4.1 Germany Circulating Tumor Cells and Cancer Stem Cells Market Forecast
10.4.2 France Circulating Tumor Cells and Cancer Stem Cells Market Forecast
10.4.3 UK Circulating Tumor Cells and Cancer Stem Cells Market Forecast
10.4.4 Italy Circulating Tumor Cells and Cancer Stem Cells Market Forecast
10.4.5 Russia Circulating Tumor Cells and Cancer Stem Cells Market Forecast
10.5 Middle East & Africa Circulating Tumor Cells and Cancer Stem Cells Forecast by Region (2025-2030)
10.5.1 Egypt Circulating Tumor Cells and Cancer Stem Cells Market Forecast
10.5.2 South Africa Circulating Tumor Cells and Cancer Stem Cells Market Forecast
10.5.3 Israel Circulating Tumor Cells and Cancer Stem Cells Market Forecast
10.5.4 Turkey Circulating Tumor Cells and Cancer Stem Cells Market Forecast
10.5.5 GCC Countries Circulating Tumor Cells and Cancer Stem Cells Market Forecast
10.6 Global Circulating Tumor Cells and Cancer Stem Cells Forecast by Type (2025-2030)
10.7 Global Circulating Tumor Cells and Cancer Stem Cells Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 QIAGEN Hannover
11.1.1 QIAGEN Hannover Company Information
11.1.2 QIAGEN Hannover Circulating Tumor Cells and Cancer Stem Cells Product Offered
11.1.3 QIAGEN Hannover Circulating Tumor Cells and Cancer Stem Cells Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 QIAGEN Hannover Main Business Overview
11.1.5 QIAGEN Hannover Latest Developments
11.2 AVIVA Biosciences
11.2.1 AVIVA Biosciences Company Information
11.2.2 AVIVA Biosciences Circulating Tumor Cells and Cancer Stem Cells Product Offered
11.2.3 AVIVA Biosciences Circulating Tumor Cells and Cancer Stem Cells Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 AVIVA Biosciences Main Business Overview
11.2.5 AVIVA Biosciences Latest Developments
11.3 Epic Sciences
11.3.1 Epic Sciences Company Information
11.3.2 Epic Sciences Circulating Tumor Cells and Cancer Stem Cells Product Offered
11.3.3 Epic Sciences Circulating Tumor Cells and Cancer Stem Cells Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Epic Sciences Main Business Overview
11.3.5 Epic Sciences Latest Developments
11.4 ApoCell
11.4.1 ApoCell Company Information
11.4.2 ApoCell Circulating Tumor Cells and Cancer Stem Cells Product Offered
11.4.3 ApoCell Circulating Tumor Cells and Cancer Stem Cells Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 ApoCell Main Business Overview
11.4.5 ApoCell Latest Developments
11.5 Cynvenio Biosystems
11.5.1 Cynvenio Biosystems Company Information
11.5.2 Cynvenio Biosystems Circulating Tumor Cells and Cancer Stem Cells Product Offered
11.5.3 Cynvenio Biosystems Circulating Tumor Cells and Cancer Stem Cells Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Cynvenio Biosystems Main Business Overview
11.5.5 Cynvenio Biosystems Latest Developments
11.6 Fluxion Biosciences
11.6.1 Fluxion Biosciences Company Information
11.6.2 Fluxion Biosciences Circulating Tumor Cells and Cancer Stem Cells Product Offered
11.6.3 Fluxion Biosciences Circulating Tumor Cells and Cancer Stem Cells Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Fluxion Biosciences Main Business Overview
11.6.5 Fluxion Biosciences Latest Developments
11.7 Rarecells
11.7.1 Rarecells Company Information
11.7.2 Rarecells Circulating Tumor Cells and Cancer Stem Cells Product Offered
11.7.3 Rarecells Circulating Tumor Cells and Cancer Stem Cells Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Rarecells Main Business Overview
11.7.5 Rarecells Latest Developments
11.8 Janssen Diagnostics
11.8.1 Janssen Diagnostics Company Information
11.8.2 Janssen Diagnostics Circulating Tumor Cells and Cancer Stem Cells Product Offered
11.8.3 Janssen Diagnostics Circulating Tumor Cells and Cancer Stem Cells Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Janssen Diagnostics Main Business Overview
11.8.5 Janssen Diagnostics Latest Developments
11.9 CellTraffix
11.9.1 CellTraffix Company Information
11.9.2 CellTraffix Circulating Tumor Cells and Cancer Stem Cells Product Offered
11.9.3 CellTraffix Circulating Tumor Cells and Cancer Stem Cells Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 CellTraffix Main Business Overview
11.9.5 CellTraffix Latest Developments
11.10 Silicon Biosystems
11.10.1 Silicon Biosystems Company Information
11.10.2 Silicon Biosystems Circulating Tumor Cells and Cancer Stem Cells Product Offered
11.10.3 Silicon Biosystems Circulating Tumor Cells and Cancer Stem Cells Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Silicon Biosystems Main Business Overview
11.10.5 Silicon Biosystems Latest Developments
11.11 Advanced Cell Diagnostics
11.11.1 Advanced Cell Diagnostics Company Information
11.11.2 Advanced Cell Diagnostics Circulating Tumor Cells and Cancer Stem Cells Product Offered
11.11.3 Advanced Cell Diagnostics Circulating Tumor Cells and Cancer Stem Cells Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Advanced Cell Diagnostics Main Business Overview
11.11.5 Advanced Cell Diagnostics Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂